Evotaz (atazanavir + cobicistat)

Evotaz (3641)


Evotaz is a single film-coated tablet that contains atazanavir (300 mg) plus the booster cobicistat (150 mg).

Evotaz was approved in the EU and the US in January 2015.

See also: atazanavir and cobicistat.

The European patient information and detailed Product Information for Evotaz are available from this link at the European Medicines Agency (EMA) website.

The Patient Information is a simplified summary: what the drug is, why it is used, results from studies and cautions including side effects.

The Product Information is a detailed technical summary that you can access as a PDF file by clicking the ‘Product Information’ tab. It describes more precisely how the drug works and how it is processed by your body. This includes, for example, reported food interaction studies in terms of calories or fat content. It includes more details of the study results and a full list of side effects and drug interactions.